The enhanced precision used in 3D printing can drive efficiencies in early drug development by allowing more flexibility with dosage size and strengths, leading to a more effective use of costly resources.
To address the limitations of oral solid dose forms while also keeping pace with advances in patient treatment, pharmaceutical manufacturers must be willing to consider alternative approaches to developing and manufacturing OSD drugs.
3D printing allows drug companies to not only boost efficacy and adherence but also contribute to their brand longevity by expanding and capturing market share with other dosage form options.
Mixer testing simulation trials are needed to confirm the suitability of a specific mixing strategy. This white paper explores five ways to increase energy efficiency in new and existing mixing processes.
Natoli Engineering Company recently completed a successful Factory Acceptance Test (FAT) with a top-tier cosmetics company.
When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scale- up and performance of the formulation at production levels. By Chuck Kettler, Director, Natoli Scientific of Natoli Engineering Company, Inc.
Almac has developed a flexible pediatric dosage form consisting of minitablets filled into stickpacks using a robust manufacturing and filling process suitable for routine commercial manufacture.
Providing support in all aspects of the tablet compression process should be expected from your tooling and tablet press partner.
Clinical studies on solid dose products may require a placebo. The placebo, in the case of a tablet, should possess the same shape and color compared to the active product.
Comparative human in-vivo study of an immediate release tablet over-encapsulated by gelatin and hydroxypropyl methyl cellulose capsules – impact of dissolution rate on bioequivalence.
|
|
|
|
|
|
|
|
|